Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice

被引：5

作者：

Okamoto, Masahiro ^{[1
]}

Tajiri, Wakako ^{[1
]}

Ueo, Hiroki ^{[1
]}

Masuda, Takanobu ^{[1
]}

Ijichi, Hideki ^{[1
]}

Koga, Chinami ^{[1
]}

Nakamura, Yoshiaki ^{[1
]}

Taguchi, Kenichi ^{[2
]}

Ohno, Shinji ^{[3
]}

Tokunaga, Eriko ^{[1
]}

机构：

[1] Natl Hosp Org Kyushu Canc Ctr, Dept Breast Oncol, Fukuoka, Japan

[2] Natl Hosp Org Kyushu Canc Ctr, Dept Pathol, Fukuoka, Japan

[3] Canc Inst Hosp, Breast Canc Ctr, Tokyo, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 06期

关键词：

Breast cancer; HER2; trastuzumab; DOUBLE-BLIND; PERTUZUMAB; NERATINIB; DOCETAXEL; SURVIVAL; EXTENET; RELAPSE; HER-2;

D O I：

10.21873/anticanres.14314

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To evaluate the improvement in the prognosis by adjuvant trastuzumab in clinical practice and the risk factors for distant recurrence, we retrospectively investigated the prognosis of HER2-positive early breast cancer in our department before and after the introduction of adjuvant trastuzumab. Patients and Methods: Cohorts A and B included 161 and 182 cases, respectively, who underwent surgery before (2000-2007) and after (2008-2015) the introduction of adjuvant trastuzumab. Results: The rates of relapse-free and distant metastasis-free survival were significantly better in cohort B than in cohort A. The risk factors of distant recurrence found in cohort A, such as the presence of lymph node metastasis, lymphatic invasion, and a low histological grade, did not increase the risk in cohort B. Conclusion: Many risk factors seemed to have been negated by adjuvant trastuzumab administration. Therefore, further escalation of adjuvant treatment should be carefully considered.

引用

页码：3315 / 3323

页数：9

共 27 条

[1] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[2]

BONADONNA G, 1977, CANCER-AM CANCER SOC, V39, P2904, DOI 10.1002/1097-0142(197706)39:6<2904::AID-CNCR2820390677>3.0.CO

[3]

2-8

[4] Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].

Chan, Arlene ;

Delaloge, Suzette ;

Holmes, Frankie A. ;

Moy, Beverly ;

Iwata, Hiroji ;

Harvey, Vernon J. ;

Robert, Nicholas J. ;

Silovski, Tajana ;

Gokmen, Erhan ;

von Minckwitz, Gunter ;

Ejlertsen, Bent ;

Chia, Stephen K. L. ;

Mansi, Janine ;

Barrios, Carlos H. ;

Gnant, Michael ;

Buyse, Marc ;

Gore, Ira ;

Smith, John, II ;

Harker, Graydon ;

Masuda, Norikazu ;

Petrakova, Katarina ;

Guerrero Zotano, Angel ;

Iannotti, Nicholas ;

Rodriguez, Gladys ;

Tassone, Pierfrancesco ;

Wong, Alvin ;

Bryce, Richard ;

Ye, Yining ;

Yao, Bin ;

Martin, Miguel .

LANCET ONCOLOGY, 2016, 17 (03) :367-377

[5] Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study [J].

Conte, P. ;

Frassoldati, A. ;

Bisagni, G. ;

Brandes, A. A. ;

Donadio, M. ;

Garrone, O. ;

Piacentini, F. ;

Cavanna, L. ;

Giotta, F. ;

Aieta, M. ;

Gebbia, V. ;

Molino, A. ;

Musolino, A. ;

Ferro, A. ;

Maltoni, R. ;

Danese, S. ;

Zamagni, C. ;

Rimanti, A. ;

Cagossi, K. ;

Russo, A. ;

Pronzato, P. ;

Giovanardi, F. ;

Moretti, G. ;

Lombardo, L. ;

Schirone, A. ;

Beano, A. ;

Amaducci, L. ;

Bajardi, E. A. ;

Vicini, R. ;

Balduzzi, S. ;

D'Amico, R. ;

Guarneri, V. ;

Giarratano, Tommaso ;

McMahon, Laura ;

De Salvo, Gian Luca ;

Dieci, Maria Vittoria ;

Maiorana, Antonio ;

Ficarra, Guido ;

Caggia, Federica ;

Grisolia, Deborah ;

Bartolini, Stefania ;

Lorusso, Vito ;

Ardito, Raffaele ;

Tartarone, Alfredo ;

Vanella, Paola ;

Taverniti, Cristiana ;

Porpiglia, Mauro ;

Spanu, Pier Giorgio ;

Biglia, Nicoletta ;

Andreis, Daniele .

ANNALS OF ONCOLOGY, 2018, 29 (12) :2328-2333

[6] Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials [J].

De Laurentiis, Michele ;

Cancello, Giuseppe ;

D'Agostino, Diego ;

Giuliano, Mario ;

Giordano, Antonio ;

Montagna, Emilia ;

Lauria, Rossella ;

Forestieri, Valeria ;

Esposito, Angela ;

Silvestro, Lucrezia ;

Pennacchio, Roberta ;

Criscitiello, Carmen ;

Montanino, Agnese ;

Limite, Gennaro ;

Bianco, Angelo Raffaele ;

De Placido, Sabino .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) :44-53

[7] 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial [J].

Earl, Helena M. ;

Hiller, Louise ;

Vallier, Anne-Laure ;

Loi, Shrushma ;

McAdam, Karen ;

Hughes-Davies, Luke ;

Harnett, Adrian N. ;

Ah-See, Mei-Lin ;

Simcock, Richard ;

Rea, Daniel ;

Raj, Sanjay ;

Woodings, Pamela ;

Harries, Mark ;

Howe, Donna ;

Raynes, Kerry ;

Higgins, Helen B. ;

Wilcox, Maggie ;

Plummer, Chris ;

Mansi, Janine ;

Gounaris, Ioannis ;

Mahler-Araujo, Betania ;

Provenzano, Elena ;

Chhabra, Anita ;

Abraham, Jean E. ;

Caldas, Carlos ;

Hall, Peter S. ;

McCabe, Christopher ;

Hulme, Claire ;

Miles, David ;

Wardley, Andrew M. ;

Cameron, David A. ;

Dunn, Janet A. .

LANCET, 2019, 393 (10191) :2599-2612

[8] Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 [J].

Goldhirsch, A. ;

Ingle, J. N. ;

Gelber, R. D. ;

Coates, A. S. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2009, 20 (08) :1319-1329

[9] A PROGNOSTIC INDEX IN PRIMARY BREAST-CANCER [J].

HAYBITTLE, JL ;

BLAMEY, RW ;

ELSTON, CW ;

JOHNSON, J ;

DOYLE, PJ ;

CAMPBELL, FC ;

NICHOLSON, RI ;

GRIFFITHS, K .

BRITISH JOURNAL OF CANCER, 1982, 45 (03) :361-366

[10] Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial [J].

Joensuu, Heikki ;

Bono, Petri ;

Kataja, Vesa ;

Alanko, Tuomo ;

Kokko, Riitta ;

Asola, Raija ;

Utriainen, Tapio ;

Turpeenniemi-Hujanen, Taina ;

Jyrkkio, Sirkku ;

Moykkynen, Kari ;

Helle, Leena ;

Ingalsuo, Seija ;

Pajunen, Marjo ;

Huusko, Mauri ;

Salminen, Tapio ;

Auvinen, Paivi ;

Leinonen, Hannu ;

Leinonen, Mika ;

Isola, Jorma ;

Kellokumpu-Lehtinen, Pirkko-Liisa .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5685-5692

← 1 2 3 →